Impact of Imaging Agent on Clinical Decisions for Prostate Cancer patients
When patients experience biochemical recurrence, the prostate-specific antigen (PSA) level rises. However, there is no visual evidence of disease on conventional scans. A new study presented at the Genitourinary Cancers Symposium (GUCS) shows that adding an imaging agent (18F-fluciclovine) to the positron-emission tomography (PET)/CT scans provides more information, and this has a substantial impact on clinical decisions for such patients.